Business
Lilly’s Mounjaro Adds a Heart Claim, Deepening Its Blockbuster Lead
The FDA expanded tirzepatide’s label to include cutting cardiovascular risk in type 2 diabetes — a first for a GIP/GLP-1 drug and a boost for the world’s top-selling medicine.